as 11-15-2024 4:00pm EST
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Founded: | 1997 | Country: | United States |
Employees: | N/A | City: | TEMPE |
Market Cap: | 16.5B | IPO Year: | N/A |
Target Price: | $267.56 | AVG Volume (30 days): | 960.2K |
Analyst Decision: | Hold | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 5.86 | EPS Growth: | 24.62 |
52 Week Low/High: | $196.09 - $335.40 | Next Earning Date: | 10-23-2024 |
Revenue: | $3,960,519,000 | Revenue Growth: | 4.03% |
Revenue Growth (this year): | 5.72% | Revenue Growth (next year): | 6.12% |
ALGN Breaking Stock News: Dive into ALGN Ticker-Specific Updates for Smart Investing
Argus Research
5 days ago
Business Wire
5 days ago
Simply Wall St.
6 days ago
Argus Research
12 days ago
Business Wire
13 days ago
Business Wire
16 days ago
MarketWatch
17 days ago
Zacks
17 days ago
The information presented on this page, "ALGN Align Technology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.